Gritstone bio and the Coalition for Epidemic Preparedness Innovations (CEPI) have signed a funding agreement to advance the development of the former’s second-generation Covid-19 vaccine programme (CORAL) against SARS-CoV-2 variants.
Biotherapeutics company GentiBio has raised $157m through a Series A funding round, which was led by Matrix Capital Management.
German pharmaceutical firm Bayer has agreed to acquire Vividion Therapeutic to strengthen its drug discovery capabilities.
Sanofi has agreed to acquire a mRNA therapeutics firm Translate Bio to advance the use of messenger RNA (mRNA) technology across vaccines and therapeutics development.
Biopharmaceutical company Ipsen and Exicure have collaborated to research, develop, and commercialize novel Spherical Nucleic Acids (SNAs) as potential investigational therapies to treat Angelman syndrome and Huntington’s disease.
Takeda Pharmaceutical has announced collaboration with Frazier Healthcare Partners to launch HilleVax to develop and commercialise the former’s clinical stage norovirus vaccine candidate, HIL-214 (formerly TAK-214).
Deep Genomics has raised $180m funding in Series C financing round to expand its artificial intelligence (AI) discovery platform for ‘Programmable’ RNA therapeutics and scale its portfolio into the clinic.
AbbVie has extended its collaboration with Calico Life Sciences to discover and develop new therapies for patients with age-related diseases, including neurodegeneration and cancer.
Biotechnology company Amgen has agreed to acquire Teneobio, a privately held clinical stage biotechnology firm, in a deal valued at about $900m.
PerkinElmer has signed an agreement to acquire US-based BioLegend, a life science antibodies and reagents provider, in a deal valued at about $5.25bn.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.